Avalyn Pharma Inc. (AVLN): who owns it and who trades it
As of Nov 12, 2026, AVLN insiders reported 4 open-market sales worth $6.7M and 3 purchases worth $20M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Fmr Llc (10% owner), with $6.7M.
Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, AVLN insiders reported $20M of open-market purchases and $6.7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Fmr Llc | 10% owner | Sale | 5,565 | $29.56 | $165K | Form 4 |
| Nov 10, 2026 | Fmr Llc | 10% owner | Sale | 47,889 | $30.28 | $1.5M | Form 4 |
| Nov 9, 2026 | Fmr Llc | 10% owner | Sale | 173,661 | $29.06 | $5M | Form 4 |
| Nov 9, 2026 | Fmr Llc | 10% owner | Sale | 1,339 | $29.75 | $39.8K | Form 4 |
| May 1, 2026 | Novo Holdings A/S | 10% owner | Purchase | 555,555 | $18.00 | $10M | Form 4 |
| May 1, 2026 | Jill Carroll | Director | Purchase | 277,778 | $18.00 | $5M | Form 4 |
| May 1, 2026 | Simeon George +1 | 10% owner | Purchase | 277,777 | $18.00 | $5M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Novo Holdings A/S | 10% owner | $10M | – | May 1, 2026 |
| Fmr Llc | 10% owner | – | $6.7M | Nov 10, 2026 |
| Jill Carroll | Director | $5M | – | May 1, 2026 |
| Simeon George | 10% owner | $5M | – | May 1, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AVLN short interest
Moderate short interest. 5.2% of AVLN shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went up 309%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.30M AVLN shares were sold short, 5.2% of the shares outstanding, down 2.2% from the report before. At the average daily volume of 434,319 shares, buying them all back would take about 5.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.30M | 5.19% | -2% | 434,319 | 5.3 |
| Oct 15, 2026 | 2.35M | 5.31% | -6% | 355,244 | 6.6 |
| Sep 30, 2026 | 2.52M | 5.68% | +20% | 295,206 | 8.5 |
| Sep 15, 2026 | 2.09M | 4.72% | +8% | 218,924 | 9.6 |
| Aug 31, 2026 | 1.93M | 4.35% | -7% | 170,146 | 11.3 |
| Aug 14, 2026 | 2.07M | 4.68% | +3% | 189,679 | 10.9 |
| Jul 31, 2026 | 2.02M | 4.55% | -8% | 215,736 | 9.4 |
| Jul 15, 2026 | 2.19M | 4.94% | +1% | 389,906 | 5.6 |
| Jun 30, 2026 | 2.17M | 4.88% | +65% | 704,258 | 3.1 |
| Jun 15, 2026 | 1.31M | 2.95% | +46% | 236,671 | 5.5 |
| May 29, 2026 | 896,139 | – | +59% | 278,129 | 3.2 |
| May 15, 2026 | 562,374 | – | – | 416,629 | 1.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Avalyn Pharma company events
Avalyn Pharma filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Sep 16, 2026.
- Sep 16, 2026LeadershipUpon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors of Avalyn Pharma Inc., the Board appointed Robert Meyer, M.D. to the Board as a Class II director for an initial term expiring at the annual meeting of stockholders in 2028. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jul 1, 2026AgreementAvalyn Pharma Inc. entered into a First Amendment to the Sublease, which amends that certain Sublease Agreement with CRISPR Therapeutics, Inc., dated as of August 29, 2025, providing for the lease of approximately 8,774 rentable square feet in the building located at 105 West First Street, Boston… Filing
- Jun 17, 2026AnnouncementShared information with investors. Filing
- Jun 3, 2026ResultsReleased financial results. Filing
- May 1, 2026RulesChanged its bylaws or articles. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Questions about Avalyn Pharma Inc. (AVLN) stock
Are AVLN insiders buying or selling?
In the last 12 months, AVLN insiders reported 3 open-market purchases worth $20M and 4 sales worth $6.7M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in AVLN?
As of Oct 30, 2026, 2.30M AVLN shares were sold short, 5.2% of the shares outstanding, down 2.2% from the report before. At the average daily volume of 434,319 shares, buying them all back would take about 5.3 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.